We are live on ! Find out more
GILD icon

Gilead Sciences

1,188 hedge funds and large institutions have $116B invested in Gilead Sciences in 2014 Q1 according to their latest regulatory filings, with 162 funds opening new positions, 513 increasing their positions, 411 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 162 | Existing positions closed: 59

25% more repeat investments, than reductions

Existing positions increased: 513 | Existing positions reduced: 411

8% more funds holding

Funds holding: 1,1001,188 (+88)

2.58% more ownership

Funds ownership: 92.73%95.31% (+2.6%)

6% less capital invested

Capital invested by funds: $124B → $116B (-$7.35B)

26% less funds holding in top 10

Funds holding in top 10: 151112 (-39)

47% less call options, than puts

Call options by funds: $1.3B | Put options by funds: $2.47B

Holders
1,188
Holders Change
+88
Holders Change %
+8%
% of All Funds
34.19%
Holding in Top 10
112
Holding in Top 10 Change
-39
Holding in Top 10 Change %
-25.83%
% of All Funds
3.22%
New
162
Increased
513
Reduced
411
Closed
59
Calls
$1.3B
Puts
$2.47B
Net Calls
-$1.17B
Net Calls Change
+$671M

GILD Hedge Fund Activity: Q1 2014 in Review

1,188 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2014, worth a combined $116B — down 6% from $124B a quarter earlier.

Buyers outnumbered sellers: 162 funds opened new GILD positions and 59 closed out — a net gain of 103 holders — while 513 added to existing stakes and 411 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $3.64B. The largest seller was Capital World Investors, cutting an estimated $1.21B.

  • 1,188 institutional investors held Gilead Sciences (GILD) as of Q1 2014, up from 1,100 in Q4 2013.
  • Funds reported $116B of Gilead Sciences stock for Q1 2014, down 6% quarter-over-quarter.
  • 162 funds opened new Gilead Sciences positions in Q1 2014 and 59 closed out, a net change of +103 holders.
  • The largest Gilead Sciences buyer in Q1 2014 was BNP Paribas Financial Markets, an estimated $3.64B added.
  • The largest Gilead Sciences seller in Q1 2014 was Capital World Investors, an estimated $1.21B sold.

Based on aggregated 13F filings for Q1 2014.